wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC
Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
P2860
Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33438839-C4576DF9-2EB6-49A3-B948-9B4836AFB2CC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6b859459f0f0019afa860fd5699ecc052788bba9
P2860
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.